Introduction

For decades, therapeutic progress in non-malignant hematology was measured largely by incremental improvements in symptom control, such as fewer transfusions, reduced pain crises, or transient suppression of immune-mediated cytopenias. While these advances improved quality of life, they rarely changed the underlying disease trajectory.^1-4 Data presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition reflect a clear evolution in this paradigm, with therapies increasingly designed to intervene at the level of disease biology, aiming for durable remission, functional recovery, and long-term reduction in disease burden.

Five developments presented at ASH 2025 exemplify this shift toward disease modification across sickle cell disease (SCD), thalassemia, and immune-mediated hematologic and autoimmune disorders.

Gene editing in SCD: durable molecular and functional correction

Gene editing has emerged as one of the most transformative disease-modifying strategies in SCD. Updated results from the Phase I/II RUBY trial (NCT04853576) of renizgamglogene autogedtemcel demonstrated sustained biologic and clinical benefit with extended follow-up in adolescents and adults with severe disease.⁵ By targeting the BCL11A repressor binding site within the HBG1/2 promoters using CRISPR-Cas12a, this approach reactivates endogenous fetal hemoglobin (HbF) production in a manner analogous to hereditary persistence of fetal hemoglobin, a condition associated with attenuated disease severity.

Among 40 treated patients, follow-up approaching a median of 13.6 months showed near-complete elimination of vaso-occlusive events, accompanied by normalization of total hemoglobin levels and fetal hemoglobin fractions exceeding 40%. Importantly, fetal hemoglobin was distributed across the vast majority of erythrocytes, with hemoglobin per F-cell consistently above the anti-sickling threshold. Markers of hemolysis improved in parallel, supporting restoration of red cell integrity rather than compensatory erythropoiesis.

In a recent interview at ASH 2025, Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, emphasized the depth of clinical benefit observed to date: “As of the last data cutoff, 38 out of 40 patients are pain-free. We are also seeing continued improvement in pain scales and physical activity, almost back to what is reported by the normal population.”

Together, these findings support sustained molecular correction translating into durable clinical benefit. While longer-term follow-up is required to confirm long-term safety and durability, gene editing is increasingly positioned as a one-time intervention capable of altering the biological trajectory of SCD.

Enabling disease modification: stem cell mobilization as a biological target in SCD

As curative therapies for SCD become clinically viable, attention has increasingly turned to upstream barriers that limit patient access. One of the most significant challenges is inadequate hematopoietic stem cell mobilization, which excludes many patients from gene-based therapies. Conventional granulocyte colony-stimulating factor (G-CSF) is contraindicated in this population, and plerixafor alone has yielded inconsistent results.⁶

A first-in-human Phase I study (NCT05618301) presented at ASH 2025 evaluated motixafortide, a high-affinity CXCR4 inhibitor, administered alone or in combination with natalizumab, a VLA-4 inhibitor. By disrupting CXCR4- and VLA-4-mediated retention of hematopoietic stem cells within the bone marrow niche, this strategy reframes mobilization as a modifiable biological process.

Motixafortide monotherapy safely mobilized substantially higher numbers of CD34-positive cells than historical plerixafor controls, with further enhancement observed when combined with VLA-4 inhibition. Mobilization was rapid, reproducible, and achieved without severe vaso-occlusive complications. ⁷

“This is a significant unmet need in the field right now,” Zachary Crees, MD, Washington University School of Medicine, St. Louis, MO, noted during discussion of the data at ASH 2025. “We have FDA-approved gene therapies, but a large number of patients simply cannot collect enough stem cells to receive them.”

By improving the feasibility and predictability of stem cell collection, optimized mobilization strategies function as essential enabling technologies that directly expand access to disease-modifying therapies in SCD.

Metabolic modulation as disease modification in transfusion-dependent thalassemia

Transfusion-dependent thalassemia is driven by ineffective erythropoiesis and premature red cell destruction resulting from globin chain imbalance. Chronic transfusion therapy mitigates symptomatic anemia but does not correct the underlying pathophysiology and is associated with cumulative iron overload and end-organ complications.⁸ Approaches that directly target red cell biology therefore represent a shift toward disease modification rather than supportive care alone.

The Phase III ENERGIZE-T trial (NCT04770779) evaluated mitapivat, an oral allosteric activator of pyruvate kinase, in adults with transfusion-dependent alpha- or beta-thalassemia. In the overall study population, mitapivat significantly reduced transfusion burden across multiple predefined endpoints.⁹

A post hoc subgroup analysis presented at ASH 2025 focused on patients with confirmed transfusion-dependent alpha-thalassemia, a population with limited therapeutic options.¹⁰ Among 12 evaluable patients, 77.8% receiving mitapivat achieved the primary transfusion reduction endpoint, defined as a ≥50% reduction in transfusion burden with a decrease of ≥2 units in any consecutive 12-week period through week 48, compared with no patients in the placebo group. Two-thirds of mitapivat-treated patients achieved protocol-defined transfusion independence.

Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, commented on the biological rationale for the observed effects. She noted that “thalassemic red cells are under constant metabolic stress and they need more energy. By increasing ATP production, we saw a significant reduction in transfusion burden compared with placebo.”

These findings indicate that mitapivat extends beyond transfusion reduction alone. By improving red cell energetics, functional capacity, and overall disease burden, metabolic modulation with mitapivat represents a substantive advance toward disease modification in transfusion-dependent thalassemia, including alpha-thalassemia.

Immune pathway reprogramming in warm autoimmune hemolytic anemia

Warm autoimmune hemolytic anemia (wAIHA) is characterized by IgG-mediated red blood cell destruction, chronic anemia, and substantial fatigue that often persists despite standard therapy. Corticosteroids remain first-line treatment, but many patients relapse or become steroid-dependent, and subsequent options such as rituximab or splenectomy do not consistently produce durable remission. As a result, management frequently involves cycles of immunosuppression rather than sustained disease control.¹¹

The Phase IIb LUMINA2 study (NCT05002777) evaluated rilzabrutinib, an oral, reversible Bruton tyrosine kinase (BTK) inhibitor, as a targeted immunomodulatory strategy in patients with relapsed/refractory (R/R) wAIHA.¹²  Results presented at ASH 2025 showed durable hemoglobin responses, with 14 of 22 patients (64.3%) achieving a ≥2 g/dL increase from baseline by Week 24 and continuing treatment through Week 50.

A post hoc analysis demonstrated that 71.4% of hemoglobin responders achieved a clinically meaningful improvement in FACIT-F fatigue scores by Week 50, with benefits across core domains including tiredness and exhaustion. Correlative analyses showed moderate-to-strong negative associations between fatigue scores and inflammatory biomarkers (IL-10, IFN-γ, TNF-α), suggesting that fatigue in wAIHA reflects both anemia and underlying immune dysregulation.¹²

“What’s striking is not just the rise in hemoglobin,” noted David Kuter, MD, Massachusetts General Hospital, Boston, MA, “but that fatigue improved and stayed improved over a full year, tracking closely with declines in inflammatory markers like TNF and interferon-α.”

By simultaneously improving anemia and dampening inflammatory signaling, rilzabrutinib demonstrates the potential for immune pathway reprogramming rather than episodic immunosuppression, aligning biological control with meaningful improvements in patient experience. Following the results of the Phase IIb LUMINA2 trial, rilzabrutinib has been granted Breakthrough Therapy designation by the FDA and Orphan Drug designation in Japan, underscoring its regulatory recognition for a high unmet need in wAIHA.¹³

CD19 CAR T-cell therapy in autoimmune disease: treatment-free remission in the CASTLE trial

The extension of CD19-directed CAR T-cell therapy into severe autoimmune disease represents one of the most conceptually important advances presented at ASH 2025, reframing immune-mediated disorders as candidates for durable biological reset rather than chronic suppression.

Final analysis of the Phase I/II CASTLE basket trial (NCT06347718) evaluated zorpocabtagene autoleucel in patients with refractory systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies, all characterized by persistent disease activity despite multiple prior immunosuppressive therapies.¹⁴

Across 24 heavily pretreated patients, all successfully received therapy, and the trial met its primary safety endpoint. No cytokine release syndrome above grade 2 and no neurotoxicity were observed. 22 of 24 patients achieved protocol-defined response criteria, and immunosuppressive therapy was discontinued in all participants.

Summarizing the implications of these findings, Fabian Müller, MD, University Hospital Erlangen observed “All patients responded and achieved treatment-free remission. We are seeing reversal of many of the organ manifestations of their diseases.”

Deep B-cell depletion followed by reconstitution with predominantly naïve B-cells supports immune system resetting rather than chronic pharmacologic suppression.¹⁵ While longer follow-up and larger studies are required, the CASTLE trial provides compelling proof-of-concept that CD19-directed CAR T-cell therapy may represent a disease-modifying approach in selected patients with severe autoimmune disease.

A unifying shift in non-malignant hematology

Collectively, the data presented at ASH 2025 reflect a redefinition of therapeutic success in non-malignant hematology. Across gene editing, enabling technologies, metabolic modulation, immune reprogramming, and cellular therapy, the field is increasingly focused on durability, functional recovery, and long-term reduction of disease burden. Future challenges will center on defining long-term safety, durability of response, and equitable access as these strategies transition from specialized centers into broader clinical practice.

References